A Phase 1 Study of INCB161734 in People With Solid Tumors

Full Title

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Purpose

Researchers want to find the best dose of INCB161734 to use in people with advanced cancer. The people in this study have solid tumors that have spread. In addition, their cancers have a genetic mutation (change) called KRAS G12D.

INCB161734 targets and blocks the mutated KRAS G12D protein, which is found in cancer cells. By blocking this protein, INCB161734 may slow or stop the growth of your cancer. INCB161734 is taken orally (by mouth).

Contact

For more information or to see if you can join this study, please call Dr. Eileen O’Reilly’s office at 646-888-4182.